Mark Berger
Technik-/Wissenschafts-/F&E-Leiter bei GENPREX, INC.
Vermögen: 5 424 $ am 31.05.2024
Aktive Positionen von Mark Berger
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENPREX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.09.2021 | - |
Karriereverlauf von Mark Berger
Ehemalige bekannte Positionen von Mark Berger
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACTINIUM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.01.2017 | 24.09.2021 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2013 | 01.01.2017 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2011 | 01.09.2013 |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 01.03.2007 | 01.06.2011 |
GSK PLC | Corporate Officer/Principal | 01.09.2002 | 01.02.2007 |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | - | - |
University of Pennsylvania | Corporate Officer/Principal | - | - |
Ausbildung von Mark Berger
Wesleyan University | Undergraduate Degree |
The University of Virginia School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Vereinigtes Königreich | 2 |
2 |
Operativ
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 4 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 8 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
GSK PLC | Health Technology |
ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
GENPREX, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Mark Berger
- Erfahrung